ABOS
Acumen Pharmaceuticals, Inc.NASDAQHealthcare$2.70+5.88%ClosedMarket Cap: $163.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.37
P/S
0.00
EV/EBITDA
-1.22
DCF Value
$0.38
FCF Yield
-69.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-111.3%
ROA
-98.8%
ROIC
-121.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-25.2M | $-25.1M | $-0.42 | — |
| FY 2025 | $0.00 | -Infinity% | $-123.8M | $-121.3M | $-2.00 | — |
| Q3 2025 | $0.00 | NaN% | $-26.5M | $-26.5M | $-0.44 | — |
| Q2 2025 | $0.00 | NaN% | $-41.8M | $-41.0M | $-0.68 | — |
| Q1 2025 | $0.00 | NaN% | $-30.4M | $-28.8M | $-0.48 | — |
| Q4 2024 | $0.00 | -Infinity% | $-39.6M | $-37.2M | $-0.62 | — |
| FY 2024 | $0.00 | NaN% | $-114.0M | $-102.3M | $-1.71 | — |
| Q3 2024 | $0.00 | NaN% | $-32.3M | $-29.8M | $-0.50 | — |
| Q2 2024 | $0.00 | NaN% | $-24.4M | $-20.5M | $-0.34 | — |
| Q1 2024 | $0.00 | NaN% | $-17.8M | $-14.9M | $-0.25 | — |
| Q4 2023 | $0.00 | -Infinity% | $-18.5M | $-16.5M | $-0.28 | — |
| FY 2023 | $0.00 | NaN% | $-61.1M | $-52.4M | $-1.08 | — |